Jump to content

SPL - STARPHARMA HOLDINGS LIMITED


Visionary

Recommended Posts

Starpharma has completed additional antiviral testing for its SPL7013 COVID 19 nasal spray, with data generated at the Scripps Research Institute in the US showed the spray inactivating more than 99.9 per cent of SARS CoV 2, the virus that causes COVID 19.

 

The antiviral activity was evident both before and after exposure of cells to to the virus, meaning the spray could be used both before and after patients get infected.

 

We are delighted to be working with Professor Gallay to expedite the development of this important product, said Starpharma chief executive Jackie Fairley. This potent virucidal action is consistent with the activity seen for SPL7013 in other viruses, including HIV and HSV.

 

Starpharma said it was rapidly advancing development of the spray and with expedited approval, the product could be ready for market in the first half of 2021.

Link to comment
Share on other sites

  • 2 weeks later...
  • Replies 2.5k
  • Created
  • Last Reply

Top Posters In This Topic

Top Posters In This Topic

Posted Images

  • 1 month later...
  • 1 year later...

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×
×
  • Create New...